

What is claimed is:

SB B1

1. A vaccine which is protective against *Mycoplasma bovis* clinical disease in a bovine species comprising at least one inactivated or attenuated *Mycoplasma bovis* biotype and a pharmaceutically acceptable excipient.

SB C1

2. The vaccine of claim 1, further comprising a suitable adjuvant.

3. The vaccine of claim 1, wherein the amount of each inactivated biotype is at least 10^8 *M. bovis* cell equivalents.

4. The vaccine of claim 1, wherein the amount of each attenuated biotype is at least 10^5 *M. bovis* cells.

SB B2

5. The vaccine of claim 1, wherein at least one of the inactivated or attenuated *Mycoplasma bovis* biotypes is selected from the group consisting of biotype A, biotype B and Biotype C.

SB C2

6. The vaccine of claim 5, wherein the amount of each selected inactivated *Mycoplasma bovis* biotype is at least 10^8 *M. bovis* cell equivalents.

7. The vaccine of claim 5, wherein the amount of each selected attenuated *Mycoplasma bovis* biotype is at least 10^5 *M. bovis* cells.

8. A vaccine which is protective against *Mycoplasma bovis* clinical disease in a bovine species comprising at least two inactivated or attenuated *Mycoplasma bovis* biotypes and a pharmaceutically acceptable excipient.

9. The vaccine of claim 8, further comprising a suitable adjuvant.

10. The vaccine of claim 8, wherein the amount of each inactivated biotype is at least 10^8 *M. bovis* cell equivalents.

ESB
C1

11. The vaccine of claim 8, wherein the amount of each attenuated biotype is at least 10^5 *M. bovis* cells.

12. The vaccine of claim 8, wherein the *Mycoplasma bovis* biotype is selected from the group consisting of biotype A, biotype B and biotype C.

13. A method for immunizing bovine animals against clinical disease caused by *Mycoplasma bovis* comprising administering to a bovine animal immunogenic amounts of at least one inactivated or attenuated *Mycoplasma bovis* biotype to elicit a protective immune response by the animal.

14. The method of claim 13, wherein at least one of the *M. bovis* biotypes is selected from the group consisting of biotype A, biotype B and biotype C.

15. The method of claim 13, wherein the vaccine is administered by injection.

16. The method of claim 13, wherein the vaccine is administered by inhalation.

17. The method of claim 13, wherein the vaccine is administered by ingestion.

18. A method for producing a *Mycoplasma bovis* vaccine comprising contacting at least one live *Mycoplasma bovis* biotype with an inactivating material, and combining the inactivated *Mycoplasma bovis* biotype with a pharmaceutically acceptable excipient to produce a *Mycoplasma bovis* vaccine.

19. The method of claim 18, further comprising mixing said inactivated *Mycoplasma bovis* biotype with a suitable adjuvant.

20. A method for immunizing bovine animals against disease caused by *Mycoplasma bovis* comprising administering to a bovine animal the vaccine of claim 8 to elicit a protective immune response by the animal.

AdJ
AdJ 37